EpCAM在子宫内膜癌肿瘤进展及临床预后中的作用
本研究探讨EpCAM与子宫内膜癌的关系:免疫组化与生物信息学分析显示低EpCAM表达与晚期及淋巴结转移相关,高表达利于生存;体外和原位小鼠模型显示EpCAM沉默促进细胞侵袭和淋巴结转移;雌激素受体α信号通过增强启动子活性调控EpCAM表达;Connectivity MAP分析显示transamin抑制EpCAM沉默细胞的侵袭性。
要点
- 低EpCAM表达与子宫内膜样癌晚期及淋巴结转移相关,高表达利于生存。
- EpCAM沉默促进子宫内膜癌细胞侵袭,重新表达可减弱侵袭性。
- Connactivity MAP分析显示transamin抑制EpCAM沉默细胞的侵袭性。
核心结论
- EpCAM缺失可能增加子宫内膜癌的恶性程度,这些发现为EpCAM在子宫内膜癌患者中的预后作用提供了新见解。
研究设计与样本
- 研究采用免疫组化染色和生物信息学分析评估EpCAM表达的临床意义,并在体外Transwell侵袭实验和原位子宫内肿瘤注射模型中研究低EpCAM表达细胞的迁移能力,同时使用Connectivity MAP识别有效抑制低EpCAM表达细胞的药物。
主要发现
- 免疫组化分析显示,低EpCAM表达与子宫内膜样癌患者的晚期及淋巴结转移相关,高EpCAM表达利于生存。
- EpCAM沉默促进细胞侵袭,在EpCAM沉默的子宫内膜癌细胞中重新表达EpCAM可减弱其侵袭性。
- 在原位子宫植入模型中抑制EpCAM促进子宫内膜癌细胞的淋巴结转移。
- 定量PCR和启动子报告基因分析显示,雌激素受体α信号通过增强启动子活性调控EpCAM表达。
- Connectivity MAP分析显示,transamin抑制EpCAM沉默的子宫内膜癌细胞的侵袭性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: EpCAM is a transmembrane glycoprotein that functions as an epithelial marker in endometrial tissues. However, the correlation between EpCAM and endometrial carcinoma (EC) is not clear. METHODS: This study investigated the association between EpCAM and EC. Immunohistochemistry staining and bioinformatics analysis disclosed the clinical importance of low EpCAM expression. The migratory ability of cells expressing low EpCAM levels was studied in transwell invasion assays in vitro and an orthotopic intra-uterine tumor injection model in vivo. The Connectivity MAP was used to identify drugs that effectively inhibit cells with low EpCAM expression. RESULTS: According to immunohistochemistry analysis results, low EpCAM expression was associated with an advanced stage and lymph node metastasis in patients with endometrioid EC, and high EpCAM expression favored survival. EpCAM silencing promoted cell invasion, and EpCAM re-expression in EpCAM-silenced EC cells attenuated their invasiveness. EpCAM suppression in an orthotopic uterine implantation model promoted the lymph node metastasis of EC cells. According to quantitative PCR and promoter reporter analyses, estrogen receptor alpha signaling regulated EpCAM expression by enhancing its promoter activity. As shown in the Connectivity MAP analysis, transamin inhibited the invasiveness of EpCAM-silenced EC cells. CONCLUSIONS: The loss of EpCAM may increase the malignancy of EC, and these findings provide new insights into the prognostic role of EpCAM in patients with EC.
引用
- Wen KC, Sung PL, Chou YT, et al. The role of EpCAM in tumor progression and the clinical prognosis of endometrial carcinoma. Gynecol Oncol. 2017. PMID: 29208367. doi:10.1016/j.ygyno.2017.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。